Agenus Inc (AGEN) 9.17 $AGEN
Will Agenus (AGEN) Disappoint Investors this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 1:15PM CDT
Agenus (AGEN) carries a Zacks Rank #3 (Hold) with an Earnings ESP of 0.00% and is scheduled to report second-quarter 2015 results on Jul 23, 2015.
AGEN: 9.17 (-0.27), MDCO: 33.85 (+0.13), MRK: 58.67 (-0.33), GSK: 42.63 (-0.39)
Agenus licenses rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1
M2 - Tue Jul 21, 5:54AM CDT
Immunology company Agenus (NasdaqCM:AGEN) disclosed on Monday the completion of the acquisition of the rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1) from Diatheva srl, an Italian biotech company controlled by SOL SpA.
AGEN: 9.17 (-0.27)
Agenus Acquires Novel Antibodies to Immuno-oncology Target CEACAM1
Business Wire - Mon Jul 20, 6:00AM CDT
Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that it has acquired rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein expressed on T cell and NK cell lymphocytes from Diatheva s.r.l., an Italian biotech company controlled by SOL S.p.A. CEACAM1 is overexpressed in melanoma, bladder, lung, colon, pancreas, and gastric cancers and has been shown to modulate innate and adaptive immune suppression in pre-clinical studies. Antibodies targeting CEACAM1 are thought to have the potential to effectively treat cancer alone or in combination with other checkpoint modulator antibodies, including those in Agenus' development pipeline.
AGEN: 9.17 (-0.27)
These 2 Stocks Doubled in 2015 -- Is 1 Still a Buy?
George Budwell, The Motley Fool - Motley Fool - Sat Jul 18, 10:03AM CDT
With 2015 halfway over, it's a good time to take a look at the best performing stocks so far and consider if they remain compelling buys heading into the back end of the year. Among healthcare stocks, for instance, Advaxis and Agenus have been...
AGEN: 9.17 (-0.27), ADXS: 18.32 (+0.04)
Agenus to Report Second Quarter 2015 Financial Results on July 23, 2015; Conference Call to Follow
Business Wire - Thu Jul 16, 3:00PM CDT
Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, will release its second quarter 2015 financial results before the market opens on Thursday, July 23, 2015. Agenus executives will host a conference call at 11:00 a.m. Eastern Time the same day.
AGEN: 9.17 (-0.27)
Why Agenus (AGEN) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 29, 7:46AM CDT
Agenus could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
AGEN: 9.17 (-0.27)
Buy Lowe's - Cramer's Lightning Round (6/26/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Jun 29, 4:34AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, June 26. Bullish Calls: Lowe's (NYSE: LOW ): "You should be a buyer of Lowe's." Cramer prefers Home Depot (NYSE: HD ) but likes Lowe's as well. ...
AGEN: 9.17 (-0.27), HD: 113.86 (+0.45), PCL: 40.17 (-0.54), LOW: 66.39 (-0.31), HEES: 16.03 (-0.37), KKR: 24.20 (+0.44), IDTI: 20.76 (+0.15), CSX: 31.86 (-0.14), URI: 78.77 (-0.43)
'Mad Money' Lightning Round: Buy Lowe's and Integrated Device Technology
at The Street - Sat Jun 27, 5:00AM CDT
Cramer says take your losses on H&E Equip Services, Agenus is just an OK company and be careful with CSX and Kohlberg Kravis Roberts.
AGEN: 9.17 (-0.27), HD: 113.86 (+0.45), PCL: 40.17 (-0.54), LOW: 66.39 (-0.31), HEES: 16.03 (-0.37), KKR: 24.20 (+0.44), IDTI: 20.76 (+0.15), CSX: 31.86 (-0.14)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Jun 26, 7:09PM CDT
Cramer sees a week bookended by Greece and the monthly jobs report, with many company earnings for good measure.
AMBA: 118.18 (+0.46), MU: 18.88 (-0.01), HD: 113.86 (+0.45), NKE: 112.99 (-0.14), CAG: 44.02 (-0.27), AVAV: 27.36 (-0.82), STZ: 116.99 (-0.93), PCL: 40.17 (-0.54), M: 71.67 (-0.47), LBIO: 9.77 (-0.21), KKR: 24.20 (+0.44), EGRX: 87.74 (-2.83), IDTI: 20.76 (+0.15), CSX: 31.86 (-0.14), FINL: 27.56 (-0.13), AGEN: 9.17 (-0.27), PAYX: 47.27 (-0.03), RELY: 12.65 (+0.06), ONCE: 63.40 (-0.08), RHT: 78.29 (-0.90), LOW: 66.39 (-0.31), HEES: 16.03 (-0.37), GIS: 57.21 (+0.38), CSCO: 27.84 (-0.19)
Agenus Gets Billion-Dollar Valuation From Analyst Based on Cancer Drug That Doesn't Exist
at The Street - Tue Jun 23, 11:53AM CDT
We've reached the stage of the biotech bull market where a sell-side analyst can value a company on sales of a cancer drug that doesn't even exist.
AGEN: 9.17 (-0.27), MRK: 58.67 (-0.33), INCY: 113.87 (-1.90)
Agenus to Present at the 2015 JMP Securities Life Sciences Conference
Business Wire - Thu Jun 18, 2:15PM CDT
Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that the Company will present at the 2015 JMP Securities Life Sciences Conference on Tuesday, June 23rd at 12:00 p.m. Eastern Time. The conference will take place at The St. Regis New York in New York City.
AGEN: 9.17 (-0.27)
The Makings Of A Biotech Bubble
Bret Jensen - at Seeking Alpha - Wed Jun 17, 12:06PM CDT
AGEN: 9.17 (-0.27), CRIS: 3.50 (+0.09), TTPH: 51.28 (+0.01), XBI: 266.35 (-4.58), IBB: 395.49 (-2.51), ABBV: 70.54 (-0.26), EGRX: 87.74 (-2.83), PRTA: 61.08 (-1.75), CELG: 136.24 (+1.01)
Agenus Appoints C. Evan Ballantyne as Chief Financial Officer
Business Wire - Wed Jun 17, 6:00AM CDT
Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced the appointment of C. Evan Ballantyne as the Company's Chief Financial Officer, effective immediately. Mr. Ballantyne will be responsible for all aspects of the Company's financial, accounting, investor relations and corporate communication functions.
AGEN: 9.17 (-0.27)
Agenus (AGEN) Stock Higher Following Coverage Initiation
at The Street - Thu Jun 11, 9:39AM CDT
Shares of Agenus (AGEN) are surging on Thursday after analysts at Oppenheimer initiated coverage of the company with an 'outperform' rating and a price target of $14.
AGEN: 9.17 (-0.27)
Cancer Drugs: 2 Stocks to Watch
George Budwell, The Motley Fool - Motley Fool - Sun Jun 07, 12:06PM CDT
The treatment of cancer is undergoing a potential revolution with the advent of powerful new immunotherapies and small molecule, all-oral treatments. The ultimate goal is to develop chemotherapy-free treatment regimens that are more effective and...
AGEN: 9.17 (-0.27), ADXS: 18.32 (+0.04), MRK: 58.67 (-0.33), INCY: 113.87 (-1.90), AZN: 67.64 (-0.21), BMY: 68.87 (-1.10), CELG: 136.24 (+1.01)
Agenus Gains after Merck Extends Immuno-Oncology Ties - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 04, 1:25PM CDT
Agenus (AGEN) and Merck (MRK) extend their year-old collaboration and licensing immuno-oncology agreement to Apr 2016.
AGEN: 9.17 (-0.27), MRK: 58.67 (-0.33), INCY: 113.87 (-1.90)
Merck extends collaboration with Agenus to April 2016
Seeking Alpha - at Seeking Alpha - Wed Jun 03, 9:23AM CDT
AGEN: 9.17 (-0.27), MRK: 58.67 (-0.33)
Merck Extends Immuno-Oncology Collaboration with Agenus
Business Wire - Wed Jun 03, 6:00AM CDT
Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, announced today that Merck, known as MSD outside the United States and Canada, through a subsidiary, has extended its collaborative research term under its existing collaboration and license agreement with Agenus, for the discovery and development of therapeutic antibodies to Merck proprietary immune checkpoints for the treatment of cancer.
AGEN: 9.17 (-0.27), MRK: 58.67 (-0.33)
Updated Phase 2 Data of Prophage In Newly Diagnosed GBM Presented at ASCO Show Improvement in Median Progression Free Survival and Overall Survival Independently of Prognostic Markers, Compared with Historical Expectations
Business Wire - Mon Jun 01, 6:00AM CDT
--Improvement in overall survival seen independent of MGMT methylation status
AGEN: 9.17 (-0.27)
Agenus: Even After Rally; Shares Still Have Upside
Bret Jensen - at Seeking Alpha - Fri May 29, 8:40AM CDT
AGEN: 9.17 (-0.27)
Will Agenus (AGEN) Disappoint Investors this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 1:15PM CDT
Agenus (AGEN) carries a Zacks Rank #3 (Hold) with an Earnings ESP of 0.00% and is scheduled to report second-quarter 2015 results on Jul 23, 2015.
AGEN: 9.17 (-0.27), MDCO: 33.85 (+0.13), MRK: 58.67 (-0.33), GSK: 42.63 (-0.39)
Agenus licenses rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1
M2 - Tue Jul 21, 5:54AM CDT
Immunology company Agenus (NasdaqCM:AGEN) disclosed on Monday the completion of the acquisition of the rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1) from Diatheva srl, an Italian biotech company controlled by SOL SpA.
AGEN: 9.17 (-0.27)
Agenus Acquires Novel Antibodies to Immuno-oncology Target CEACAM1
Business Wire - Mon Jul 20, 6:00AM CDT
Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that it has acquired rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein expressed on T cell and NK cell lymphocytes from Diatheva s.r.l., an Italian biotech company controlled by SOL S.p.A. CEACAM1 is overexpressed in melanoma, bladder, lung, colon, pancreas, and gastric cancers and has been shown to modulate innate and adaptive immune suppression in pre-clinical studies. Antibodies targeting CEACAM1 are thought to have the potential to effectively treat cancer alone or in combination with other checkpoint modulator antibodies, including those in Agenus' development pipeline.
AGEN: 9.17 (-0.27)
These 2 Stocks Doubled in 2015 -- Is 1 Still a Buy?
George Budwell, The Motley Fool - Motley Fool - Sat Jul 18, 10:03AM CDT
With 2015 halfway over, it's a good time to take a look at the best performing stocks so far and consider if they remain compelling buys heading into the back end of the year. Among healthcare stocks, for instance, Advaxis and Agenus have been...
AGEN: 9.17 (-0.27), ADXS: 18.32 (+0.04)
Agenus to Report Second Quarter 2015 Financial Results on July 23, 2015; Conference Call to Follow
Business Wire - Thu Jul 16, 3:00PM CDT
Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, will release its second quarter 2015 financial results before the market opens on Thursday, July 23, 2015. Agenus executives will host a conference call at 11:00 a.m. Eastern Time the same day.
AGEN: 9.17 (-0.27)
Why Agenus (AGEN) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 29, 7:46AM CDT
Agenus could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
AGEN: 9.17 (-0.27)
Buy Lowe's - Cramer's Lightning Round (6/26/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Jun 29, 4:34AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, June 26. Bullish Calls: Lowe's (NYSE: LOW ): "You should be a buyer of Lowe's." Cramer prefers Home Depot (NYSE: HD ) but likes Lowe's as well. ...
AGEN: 9.17 (-0.27), HD: 113.86 (+0.45), PCL: 40.17 (-0.54), LOW: 66.39 (-0.31), HEES: 16.03 (-0.37), KKR: 24.20 (+0.44), IDTI: 20.76 (+0.15), CSX: 31.86 (-0.14), URI: 78.77 (-0.43)
'Mad Money' Lightning Round: Buy Lowe's and Integrated Device Technology
at The Street - Sat Jun 27, 5:00AM CDT
Cramer says take your losses on H&E Equip Services, Agenus is just an OK company and be careful with CSX and Kohlberg Kravis Roberts.
AGEN: 9.17 (-0.27), HD: 113.86 (+0.45), PCL: 40.17 (-0.54), LOW: 66.39 (-0.31), HEES: 16.03 (-0.37), KKR: 24.20 (+0.44), IDTI: 20.76 (+0.15), CSX: 31.86 (-0.14)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Jun 26, 7:09PM CDT
Cramer sees a week bookended by Greece and the monthly jobs report, with many company earnings for good measure.
AMBA: 118.18 (+0.46), MU: 18.88 (-0.01), HD: 113.86 (+0.45), NKE: 112.99 (-0.14), CAG: 44.02 (-0.27), AVAV: 27.36 (-0.82), STZ: 116.99 (-0.93), PCL: 40.17 (-0.54), M: 71.67 (-0.47), LBIO: 9.77 (-0.21), KKR: 24.20 (+0.44), EGRX: 87.74 (-2.83), IDTI: 20.76 (+0.15), CSX: 31.86 (-0.14), FINL: 27.56 (-0.13), AGEN: 9.17 (-0.27), PAYX: 47.27 (-0.03), RELY: 12.65 (+0.06), ONCE: 63.40 (-0.08), RHT: 78.29 (-0.90), LOW: 66.39 (-0.31), HEES: 16.03 (-0.37), GIS: 57.21 (+0.38), CSCO: 27.84 (-0.19)
Agenus Gets Billion-Dollar Valuation From Analyst Based on Cancer Drug That Doesn't Exist
at The Street - Tue Jun 23, 11:53AM CDT
We've reached the stage of the biotech bull market where a sell-side analyst can value a company on sales of a cancer drug that doesn't even exist.
AGEN: 9.17 (-0.27), MRK: 58.67 (-0.33), INCY: 113.87 (-1.90)
Agenus to Present at the 2015 JMP Securities Life Sciences Conference
Business Wire - Thu Jun 18, 2:15PM CDT
Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that the Company will present at the 2015 JMP Securities Life Sciences Conference on Tuesday, June 23rd at 12:00 p.m. Eastern Time. The conference will take place at The St. Regis New York in New York City.
AGEN: 9.17 (-0.27)
The Makings Of A Biotech Bubble
Bret Jensen - at Seeking Alpha - Wed Jun 17, 12:06PM CDT
AGEN: 9.17 (-0.27), CRIS: 3.50 (+0.09), TTPH: 51.28 (+0.01), XBI: 266.35 (-4.58), IBB: 395.49 (-2.51), ABBV: 70.54 (-0.26), EGRX: 87.74 (-2.83), PRTA: 61.08 (-1.75), CELG: 136.24 (+1.01)
Agenus Appoints C. Evan Ballantyne as Chief Financial Officer
Business Wire - Wed Jun 17, 6:00AM CDT
Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced the appointment of C. Evan Ballantyne as the Company's Chief Financial Officer, effective immediately. Mr. Ballantyne will be responsible for all aspects of the Company's financial, accounting, investor relations and corporate communication functions.
AGEN: 9.17 (-0.27)
Agenus (AGEN) Stock Higher Following Coverage Initiation
at The Street - Thu Jun 11, 9:39AM CDT
Shares of Agenus (AGEN) are surging on Thursday after analysts at Oppenheimer initiated coverage of the company with an 'outperform' rating and a price target of $14.
AGEN: 9.17 (-0.27)
Cancer Drugs: 2 Stocks to Watch
George Budwell, The Motley Fool - Motley Fool - Sun Jun 07, 12:06PM CDT
The treatment of cancer is undergoing a potential revolution with the advent of powerful new immunotherapies and small molecule, all-oral treatments. The ultimate goal is to develop chemotherapy-free treatment regimens that are more effective and...
AGEN: 9.17 (-0.27), ADXS: 18.32 (+0.04), MRK: 58.67 (-0.33), INCY: 113.87 (-1.90), AZN: 67.64 (-0.21), BMY: 68.87 (-1.10), CELG: 136.24 (+1.01)
Agenus Gains after Merck Extends Immuno-Oncology Ties - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 04, 1:25PM CDT
Agenus (AGEN) and Merck (MRK) extend their year-old collaboration and licensing immuno-oncology agreement to Apr 2016.
AGEN: 9.17 (-0.27), MRK: 58.67 (-0.33), INCY: 113.87 (-1.90)
Merck extends collaboration with Agenus to April 2016
Seeking Alpha - at Seeking Alpha - Wed Jun 03, 9:23AM CDT
AGEN: 9.17 (-0.27), MRK: 58.67 (-0.33)
Merck Extends Immuno-Oncology Collaboration with Agenus
Business Wire - Wed Jun 03, 6:00AM CDT
Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, announced today that Merck, known as MSD outside the United States and Canada, through a subsidiary, has extended its collaborative research term under its existing collaboration and license agreement with Agenus, for the discovery and development of therapeutic antibodies to Merck proprietary immune checkpoints for the treatment of cancer.
AGEN: 9.17 (-0.27), MRK: 58.67 (-0.33)
Updated Phase 2 Data of Prophage In Newly Diagnosed GBM Presented at ASCO Show Improvement in Median Progression Free Survival and Overall Survival Independently of Prognostic Markers, Compared with Historical Expectations
Business Wire - Mon Jun 01, 6:00AM CDT
--Improvement in overall survival seen independent of MGMT methylation status
AGEN: 9.17 (-0.27)
Agenus: Even After Rally; Shares Still Have Upside
Bret Jensen - at Seeking Alpha - Fri May 29, 8:40AM CDT
AGEN: 9.17 (-0.27)
